PROCEPT BioRobotics Corp. Hits New 52-Week Low at $32.46

PROCEPT BioRobotics Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 32.46 as of October 13, 2025. This marks a significant decline, with the stock's performance over the past year showing a decrease of 51.97%, contrasting sharply with the S&P 500's gain of 13.36% during the same period.
The company's market capitalization stands at USD 2,165 million, and it has been navigating a challenging financial landscape, reflected in its negative return on equity of -21.80% and a debt-to-equity ratio of -0.65. Despite reporting positive results for the last seven consecutive quarters, PROCEPT BioRobotics has faced difficulties, including a high operating cash flow loss of USD -83.21 million and a net profit loss of USD -44.31 million.

The stock's price-to-book ratio is 5.61, indicating a premium valuation relative to its book value. Additionally, the company has a 0.00% dividend yield, further emphasizing its focus on growth rather than returning capital to shareholders. With institutional holdings at 100%, the stock remains under scrutiny as it continues to navigate its current market position.